

## MEPOLIZUMAB injection (Nucala®) for chronic rhinosinusitis with nasal polyps

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of MEPOLIZUMAB injection (Nucala®) for chronic rhinosinusitis with nasal polyps.**

### GREY

Mepolizumab has been granted a license extension and is now indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.<sup>[1]</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, prescribers should continue to follow national guidance, local pathways and local formulary choices for the management of chronic rhinosinusitis:

- > NICE Clinical Knowledge Summary: [Sinusitis](#) (March 2021)
- > Pan Mersey APC Formulary [Chapter 12: Ear, nose and oropharynx](#)

### References

1. GlaxoSmithKline UK. Summary of Product Characteristics; [Nucala 100 mg solution for injection in pre-filled pen](#), 14 January 2022. Accessed online 10 February 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.